Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/589839
Full metadata record
DC FieldValueLanguage
dc.coverage.spatial
dc.date.accessioned2024-09-18T04:21:41Z-
dc.date.available2024-09-18T04:21:41Z-
dc.identifier.urihttp://hdl.handle.net/10603/589839-
dc.description.abstractThe main objective of the current research was to design, optimize and evaluate of sustained release Etodolac extended release tablets and cilostazol sustained release tablets and to study the different formulation and process variables. INTRODUCTION: In market, 50 mg and 100 mg Immediate Release tablet is available. Daily dose of cilostazol is 200 mg/day. It is observed more side effects due to conventional dose. The sustained release cilostazol tablet has a long release time so that the sustains release cilostazol tablet can be taken once daily for convenience of drug use and minimizes the manifestation of headache which is one side effect caused when women take conventional cilostazol preparations, so that the convenience of drug use can be improved. The slow-release cilostazol tablet exhibits a stable elution pattern with no variation in release rate according to changes in pH in the stomach and intestines, as well as an effect of delaying the release of a drug, by release-controlling polymer. PLAN OF WORK: It describes the aim and objective of the research work and mentions in brief, the plan of work that was undertaken. PREFORMULATION STUDIES: Standardization of the drug was carried out for cilostazol tablet, a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating agent with respect to its organoleptic parameters, bulk characterization, solubility and stability analysis and other parameters like melting point and moisture content and has been reported in this chapter along with the literature review for the respective drugs. CONCLUSION: we report that etodolac, non-steroidal anti-inflammatory were developed with different manufacturing methods and polymers as an extended release tablets. Etodoalc ER tablets formulated with xanthan gum by wet granulation found to be enhanced than kollidon SR formulation. Cilostazol, selective inhibitor of phosphodiesterase-II were developed with different manufacturing methods and polymers as a sustained release tablets.
dc.format.extent204
dc.languageEnglish
dc.relation
dc.rightsuniversity
dc.titleImpact of Formulation and Process Variables on the Development of Extended Release Matrix Tablets
dc.title.alternative
dc.creator.researcherArunkumar Alias Arumugarajan M
dc.subject.keywordCilostazol
dc.subject.keywordEtodoalc ER tablets
dc.subject.keywordExtended Release Matrix Tablets
dc.subject.keywordFormulation
dc.subject.keywordImpact
dc.subject.keywordProcess Variables
dc.description.note
dc.contributor.guideGeetha G
dc.publisher.placeChennai
dc.publisher.universityThe Tamil Nadu Dr. M.G.R. Medical University
dc.publisher.institutionDepartment of Pharmacy
dc.date.registered2011
dc.date.completed2014
dc.date.awarded2016
dc.format.dimensions
dc.format.accompanyingmaterialNone
dc.source.universityUniversity
dc.type.degreePh.D.
Appears in Departments:Department of Pharmacy

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File515.85 kBAdobe PDFView/Open
02_prelim pages.pdf9.82 MBAdobe PDFView/Open
03_content.pdf751.82 kBAdobe PDFView/Open
05_chapter 1.pdf5.94 MBAdobe PDFView/Open
06_chapter 2.pdf1.48 MBAdobe PDFView/Open
07_chapter 3.pdf4.67 MBAdobe PDFView/Open
08_chapter 4.pdf20.87 MBAdobe PDFView/Open
09_chapter 5.pdf29.09 MBAdobe PDFView/Open
10_annexures.pdf5.02 MBAdobe PDFView/Open
10_chapter 6.pdf11.45 MBAdobe PDFView/Open
11_chapter 7.pdf3.67 MBAdobe PDFView/Open
80_recommendation.pdf3.15 MBAdobe PDFView/Open


Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).

Altmetric Badge: